LabCorp Transforms the Clinical Trial Experience And Streamlines the Drug Development Process

Advancements in Technology and Patient Access Deliver Better Clinical Trial Access, Quality, and Experiences BURLINGTON, N.C.--(BUSINESS WIRE)--Oct. 20, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced new capabilities that will transform the clinical trial experience with the goal of streamlining the drug development process. This transformation will enable LabCorp's drug development business, Covance, a global leader in decentralized clinical trials (DCTs), to quickly and efficiently connect patients to clinical trials, which will allow for better access to potential drugs, vaccines, and medical devices. Additionally, the seamless, tech-enabled, patient-centric capabilities will provide a better clinical trial experience for patients, and biopharmaceutical and medical device customers.

Copy and paste this URL:

https://biopharma.labcorp.com/latest-thinking/explore-library/detail.html/covance/assetLibrary/articles/Press-Release_20Oct20_LabCorp-Transforms-Clinical-Trial-Experience.pdf